Targets › VZVIG1
1 program from 1 company in 1 trial: 1 Phase 3; Vaccines; next expected readout Dec 2026.
Open in Phaseline: the race on VZVIG1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Luzhu Biotechnology Co., Ltd. | Recombinant Herpes Zoster Vaccine (LZ901) VZV glycoprotein E (gE) fusion protein tetramer adsorbed with aluminum hydroxide adjuvant | VZVIG1 | Phase 3 | Vaccine-Preventable Diseases | Dec 2026 |
Vaccine-Preventable Diseases (1)
other (1)
Beijing Luzhu Biotechnology Co., Ltd. (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.